Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
| Autor: | Irina Chazova, Leopoldo S. Piegas, Alexander Parkhomenko, Jackie Bosch, Patricio Lopez-Jaramillo, Hyejung Jung, Jun Zhu, Gilles R. Dagenais, Eva Lonn, Kamlesh Khunti, Karen Sliwa, Antonio L. Dans, Hope Investigators, Salim Yusuf, Petr Jansky, Basil S. Lewis, Matyas Keltai, John Varigos, Gregorio Sanchez-Vallejo, Ron J.G. Peters, Lisheng Liu, Denis Xavier, Janice Pogue, Robert S. McKelvie, Alvaro Avezum, Claes Held, William D. Toff, Katalin Keltai, Christopher M. Reid, Lawrence A. Leiter, Rafael Diaz, Prem Pais, Khalid Yusoff, Peggy Gao |
|---|---|
| Přispěvatelé: | ACS - Amsterdam Cardiovascular Sciences, APH - Amsterdam Public Health, Cardiology |
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Population Hypercholesterolemia 030204 cardiovascular system & hematology Placebo law.invention Medication Adherence 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial Double-Blind Method law Risk Factors Internal medicine medicine Humans Rosuvastatin 030212 general & internal medicine Myocardial infarction Rosuvastatin Calcium education Aged education.field_of_study Cholesterol lowering business.industry Cholesterol Intermediate risk General Medicine Cholesterol LDL Middle Aged medicine.disease Cardiovascular disease chemistry Cardiovascular Diseases Heart failure Physical therapy Female Hydroxymethylglutaryl-CoA Reductase Inhibitors business medicine.drug |
| Zdroj: | Repositorio Universidad de Santander Universidad de Santander instacron:Universidad de Santander New England journal of medicine, 374(21), 2021-2031. Massachussetts Medical Society |
| ISSN: | 0028-4793 |
| Popis: | 11 p. BACKGROUND Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated lipid levels or inflammatory markers and involved mainly white persons. It is unclear whether the benefits of statins can be extended to an intermediate-risk, ethnically diverse population without cardiovascular disease. METHODS In one comparison from a 2-by-2 factorial trial, we randomly assigned 12,705 participants in 21 countries who did not have cardiovascular disease and were at intermediate risk to receive rosuvastatin at a dose of 10 mg per day or placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, and the second coprimary outcome additionally included revascularization, heart failure, and resuscitated cardiac arrest. The median follow-up was 5.6 years. RESULTS The overall mean low-density lipoprotein cholesterol level was 26.5% lower in the rosuvastatin group than in the placebo group. The first coprimary outcome occurred in 235 participants (3.7%) in the rosuvastatin group and in 304 participants (4.8%) in the placebo group (hazard ratio, 0.76; 95% confidence interval [CI], 0.64 to 0.91; P=0.002). The results for the second coprimary outcome were consistent with the results for the first (occurring in 277 participants [4.4%] in the rosuvastatin group and in 363 participants [5.7%] in the placebo group; hazard ratio, 0.75; 95% CI, 0.64 to 0.88; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|